Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Collagen Solutions aiming to become a £100mln company

Collagen Solutions has set itself the goal of becoming a £100mln company in the next five years.
Collagen Solutions aiming to become a £100mln company
Non-human derived collagen comes from farm animals such as cows.
Collagen Solutions (LON:COS) is the marriage of three companies with significant experience in the supply development and manufacture of added value biomaterial products and is aiming to be more than simply the sum of these component parts.
 
The merger of Collbio and Collagen Solutions LLC in the UK and US, respectively, created a business with manufacturing, research, sales and marketing capabilities.
 
The addition of New Zealand’s Southern Lights Biomaterials last December gave it processing capacity as well as a customer base in Asia, meaning the business is operating in three major continents.
 
Collectively the markets it operates in are worth around £10bn annually – which makes its target of becoming a £100mln market cap business by 2020 achievable. That said it has some way to go with a valuation of £16mln currently. 
 
Most commonly found in the skin, collagen is the structural protein that supports various connective tissues.
 
Versions of collagen can be human derived, but more commonly, for medical applications, they are taken from animals such as cows, pigs, chicken and even fish.
 
Collagen tends to be used in wound care – so burns and skin grafts – prosthetic veins and arteries, bone grafts and skin regeneration. 
 
The company itself provides products in a number of different forms from raw tissue and tissue scaffolds to soluble and powdered collagen. 
 
It splits its business into three distinct streams: material supply, development services and contract manufacturing. 
 
The supply and manufacturing provides the bread and butter. The jam on top is helping larger partners create new products; in other words, embedding its technology in the new wave of collagen derived advancements. 
 
Its collagen expertise is embedded in a diabetic food ulcer treatment developed by San Diego-based Taxus Cardium, while its powdered product is used for a bone graft developed by Globus Medical, which also has US regulatory sign off. 
 
Its IP and material have also been used in a scaffold product being designed to treat burns victims.
 
“Given its development and manufacturing expertise as well as intellectual property, it is not inconceivable that in the longer term the company could develop its own products, thereby capturing greater margin and generating incremental shareholder value, although this has not been articulated by management,” said analyst Mark Brewer at the research firm Hardman & Co.
 
At the moment, at least, Collagen Solutions will remain solely a supplier of products, services and IP, according to chief executive Stewart White.
 
“We know what we are and what we are not,” he told Proactive Investors. 
 
“We are not a [medical devices giant] like Medtronic, Zimmer or Baxter. However, we would like to be in terms of revenues. But we don’t aspire to have the sales and marketing that comes with being a scaled down version of these three, nor the costs that such things incur.”
 
“What we do have is an excellent range of customers and global network in the medical devices market that we can offer our know-how and IP to.”
 
With cash on the balance sheet of £3.4mln, White is confident the company has a financial runway long enough to get it to break-even, which is forecast to occur at some point next year.
 
In his latest note, Hardman’s Brewer is predicting Collagen Solutions will turn over £1mln this passed financial year, rising to £3.7mln, then £6.5mln and £10.5mln in 2018. By that time the group is expected to generate underlying EBITDA of £4.1mln.
 
Achieving that £100mln market capitalisation means getting sales to £15-£20mln by 2020, analysts reckon.
 
“That’s the sort of valuation we think we can get if we attack the markets where we already have locations, that is, the US, Asia and Europe,” said White. 
 
“We don’t have to put everything on black or red. We have enough opportunities, products and IP to create multiple revenue streams. 
 
“In terms of reaching that £100mln valuation it could very well be a combination of organic growth and significant progress in also monetising our IP.”
 
View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
1534822132_cadoux.jpg
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use